FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular, to an antibody specifically binding to PD-L1. Also disclosed are a pharmaceutical composition and a kit containing said antibody; a polynucleotide encoding said antibody; a vector containing said polynucleotide; a host cell containing said vector. Disclosed are a method for producing said antibody and a method for treatment using said antibody.
EFFECT: invention is capable of effectively treating PD-L1-associated diseases.
27 cl, 29 ex, 18 tbl, 40 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ANTI-PD-L1 ANTIBODIES | 2017 |
|
RU2744959C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| COMBINED THERAPY FOR MALIGNANT TUMOR TREATMENT | 2016 |
|
RU2733315C2 |
| ANTI-BAG2 ANTIBODY AND METHODS OF TREATING CANCER | 2020 |
|
RU2815586C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
